The rational therapy of osteoarthritis: prospects of using combined chondroprotectors in a topical dosage forms

Authors

  • N. V. Davishnia National University of Pharmacy, Ukraine
  • I. A. Zupanets National University of Pharmacy, Ukraine
  • S. K. Shebeko National University of Pharmacy, Ukraine

DOI:

https://doi.org/10.24959/cphj.15.1358

Keywords:

osteoarthritis, rational therapy, chondroprotectors, topical dosage form

Abstract

One of the most common diseases in the structure of the pathology of the musculoskeletal system is osteoarthritis. The disease takes the fourth place among all diseases in women and the eighth - in men. Due to the significant aging of the population, including the Ukrainian population, issues of diagnosis, prevention and treatment of osteoarthritis has particular relevance. Progression of the disease leads to significant costs in the economic, social and psychological areas that are associated with the prevalence of this disease, the loss of health of patients and the high economic costs, not only in the treatment of the underlying disease, but also prevention and treatment of complications of pharmacotherapy. According to the recommendations of the «European Antirheumatic League» EULAR for osteoarthritis treatment using drugs that affect the pathogenesis of the disease and pain. Therefore, for rational treatment of the disease, international experts advised to use chondroprotectors, nonsteroidal anti-inflammatory drugs, or combinations thereof. The latter can successfully combine the effect on the metabolism of articular cartilage proteoglycan failure to impact on the articular syndrome. That pain is one of the main reasons for the decline in quality of life of patients with osteoarthritis. An important role is played by the proper choice of the dosage form, because patients with this disease require a long, almost continuous use of the drug. The use of combined drugs in topical dosage forms, can have a positive influence on the treatment of the disease, improve the quality of life of patients and partially exclude the possibility of side effects.

Author Biographies

N. V. Davishnia, National University of Pharmacy

PhD student of the Department of Clinical Pharmacology and Clinical Pharmacy

I. A. Zupanets, National University of Pharmacy

MD, Professor, Head of the Department of Clinical Pharmacology and Clinical Pharmacy.

S. K. Shebeko, National University of Pharmacy

PhD, Associate Professor of the Department of Clinical Pharmacology and Clinical Pharmacy

References

Алексеева Л.И. Применение локальных средств в лечении остеоартроза / Л.И.Алексеева, Н.Г. Кашеварова // РМЖ. – 2008, № 24. – С. 1622-1628.

Беневоленская Л. И. Эпидемиология ревматических болезней. / Л. И. Беневоленская, М. М. Бржезовский // М.: Медицина – 2008. –237 с.

Боровков Н.Н. Лекарственные средства в виде мазей в комплексной терапии остеоартроза // Тер. Архив. – 2000, № 10. – С. 72-73.

Голубев Г.Ш. Молекулярная патология остеоартроза как основа для создания патогенетически обоснованной структурно-модифицирующей терапии / Г.Ш. Голубев, О.С. Кригштейн // Международный журнал медицинской практики. – 2005. – № 2. – С. 30-37.

Державний реєстр лікарських засобів України [Електронний ресурс]. –Режим доступу : http://www.drlz.kiev.ua

Ершова О.Б. Проблема остеоартроза, пероральные и местные хондропротекторы // Справочник поликлинического врача. – 2007. – № 15. – С. 31-33.

Зупанец И.А. Клинико-фармацевтические аспекты современных комбинированных хондропротекторов / И.А. Зупанец, С.К. Шебеко // Consilium medicum – 2010. – Том 4 № 4. – С. 3-7

Коваленко В. Н. Остеоартроз. Практична настанова. / В. Н. Коваленко, О. П. Борткевич – 3-тє вид., допов., зі змінами. – К.: МОРІОН., 2010. – 608 с.

Коваленко В.М. Динамика стану здоров’я народу України та регіональні особливості (Аналітично-статистичний посібник)/ В.М. Коваленко, В.М.Корнацький – 2012. – 211 с.

Компендіум on line [Електронний ресурс]. – Режим доступу: http://compendium.com.ua

Лечение остеоартроза у больных старших возрастных групп / Г.В. Дзяк, Т.А. Симонова, М.Г. Гетман и др. // Здоров’я України. – 2011. – № 13-14. – С. 26-27.

Нові аспекти патогенезу остеоартрозу та шляхи його корекції/ В.Н. Коваленко, Н.М. Шуба, Т.Д. Воронова, Т.М. Тарасенко //Медичний часопис. – 2012. – №20 (88). – С. 5-8.

Остеоартроз: консервативная терапія : монография / под ред. Н. А. Коржа, Н. В. Дедух, И. А. Зупанца. – Х. : Золотые страницы, 2007. – 424 с.

Терафлекс в комплексной терапии остео-артроза коленных суставов и остеохондроза позвоночника / А.М. Лила, В.И. Мазуров, О.В. Шидловская, М.С. Шостак // РМЖ. Ревматология. – 2005. – Т 13, № 24. – С. 1618-1622.

Чичасова Н.В. Глюкозамин и хондроитин в лечении остеоартроза // Здоров'я України. – 2006. – № 19. – С. 48-49.

Data and statistics [Електронний ресурс]. –Режим доступу : Geneva, World Health Organization 2011 (http://www.euro.who.int/ru/what-we-do/health-topics/Life-stages/healthy-ageing/data-and-statistics/10-facts-on-healthy-ageing-in-europe)

EULAR evidence based recommendations for the diagnosis of knee osteoarthritis /W. Zhang, M. Doherty, G. Peat et al. // Ann. Rheum. Dis. – 2009. – Vol. 68, № 13. – Р. 141.

Edrigues-Monguio R., Otero M., Rovira J. Assessing the economic impact of adverse drug effects // Pharmacoeconomics. – 2003. – № 21 (9). – P. 623-650.

Fautrel B., Guillemin F. Cost of illness studies in rheumatic diseases // Current Opinion in Rheumatology. – 2002. – № 14. – Р. 121-126.

Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis / D.O. Clegg, D.J. Reda, C.L. Harris, et al. // New Engl. J. Med. – 2006. – Vol. 354. – P. 795-808.

King M.W. Glycoproteins: Roles in Cellular Homeostasis and Disease. In Encyclopedia of Molecular Cell Biology and Molecular Medicine / Ed. Robert A. Meyers. – Wiley-VCH, Weinheim, 2004. – P. 569-605.

Systematic review of topical medicines for the treatment of chronic pain / L. Mason, R.A. Moore, S. Derry et al. // BMJ. – 2004. – Vol. 328. – P. 991-994.

Kumar R Modified transdermal technologies: Breaking the barriers of drug permeation via the skin. / R Kumar, A. Philip // Trop J Pharm Res 2007; 6: 633–44.

Zhang W., Nuki G., Moskowitz R.W. et al. (2010) OARSI recommendations for the management of hip and knee osteoarthritis : part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarth. Cartil., 18(4): 476–499.

Downloads

Published

2015-09-10

Issue

Vol. 19 No. 3 (2015)

Section

Clinical Pharmacology and Pharmacotherapy

License

Copyright (c) 2015 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).